Foreword to ‘The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms’
Ce dossier présente un ensemble de revues de la littérature sur la prise en charge d'un cancer du poumon non à petites cellules de stade III
Stage III non-small-cell lung cancer (NSCLC) is a highly complex and heterogeneous disease that presents a number of challenges for achieving optimal treatment outcomes. Stage III disease affects approximately one-third of patients diagnosed with NSCLC each year and prognosis is poor, with a low cure rate. The optimal treatment regimen for patients with NSCLC is most frequently multi-modal, with systemic and local therapies for distant and local disease control, respectively. The exact sequence and modality used is debated and case-specific. The first and most important question in the management of stage III NSCLC, whether the disease is potentially resectable or not, can often be difficult to answer. If the disease is resectable, surgery after preoperative treatment (chemotherapy or chemoradiotherapy (CRT)) is an option, particularly in patients with optimal pulmonary function, mediastinal tumour clearance following upfront treatment and no requirements for pneumonectomy. However, for the remaining patients, or those who have been diagnosed with unresectable stage III NSCLC, platinum-based concurrent chemoradiotherapy (cCRT) is the standard of care versus sequential CRT.
British Journal of Cancer , éditorial en libre accès, 2020